AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats

Acta Pharmacologica Sinica

Volumn 33, Issue 1, 2012, Pages 82-90

  Schäfer, Hans Ludwig ^a   Linz, Wolfgang ^a   Falk, Eugen ^a   Glien, Maike ^a   Glombik, Heiner ^a   Korn, Marcus ^a   Wendler, Wolfgang ^a   Herling, Andreas W ^a   Rütten, Hartmut ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

AVE8134; glucose; insulin resistant ZDF rat; peroxisome proliferator activated receptor; rosiglitazone; serum lipids; transgenic human Apo A1 (hApo A1) mouse; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN A1; AVE 8134; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR GAL4; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; GLUCOSE METABOLISM; HEART WEIGHT; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; TRANSACTIVATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BENZOIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; OXAZOLES; PPAR ALPHA; RATS; RATS, ZUCKER; THIAZOLIDINEDIONES;

EID: 84855419751     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.165     Document Type: Article

References (29)

1. Kiess W, Bottner A, Bluher S, Raile K, Galler A, Kapellen TM. Type 2 diabetes mellitus in children and adolescents-the beginning of a renal catastrophe? Nephrol Dial Transplant 2004; 19: 2693-6. (Pubitemid 39480958)
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53. (Pubitemid 38579764)
3. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-4. (Pubitemid 40139973)
4. Rhodes CJ, White MF. Molecular insights into insulin action and secretion. Eur J Clin Invest 2002; 32: 3-13. (Pubitemid 41704995)
5. Agrawal RP, Sharma P, Pal M, Kochar A, Kochar DK. Magnitude of dyslipedemia and its association with micro and macro vascular complications in type 2 diabetes: a hospital based study from Bikaner (Northwest India). Diabetes Res Clin Pract 2006; 73: 211-4. (Pubitemid 43928161)
6. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007; 120: S12-8.
7. Valabhji J, Watson M, Cox J, Poulter C, Elwig C, Elkeles RS. Type 2 diabetes presenting as diabetic ketoacidosis in adolescence. Diabet Med 2003; 20: 416-7. (Pubitemid 36605628)
8. Cziraky MJ. Management of dyslipidemia in patients with metabolic syndrome. J Am Pharm Assoc 2004; 44: 478-88.
9. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6: 133-56. (Pubitemid 38220106)
10. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007; 76: 279-89. (Pubitemid 46400130)
11. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-71. (Pubitemid 46919772)
12. Patel C, Wyne KL, McGuire DK. Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? Diab Vasc Dis Res 2005; 2: 61-6. (Pubitemid 40826997)
13. Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 2006; 42: 39-64.
14. Sharpe M, Ormrod D, Jarvis B. Micronized fenofbrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels. Am J Cardiovasc Drugs 2002; 2: 125-32. (Pubitemid 34594268)
15. Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007; 297: 1362-73. (Pubitemid 46513237)
16. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fbrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 97: 2408-16. (Pubitemid 26187327)
17. Hennuyer N, Poulain P, Madsen L, Berge RK, Houdebine LM, Branellec D, et al. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response. Circulation 1999; 99: 2445-51. (Pubitemid 29218242)
18. Nadeau KJ, Ehlers LB, Aguirre LE, Reusch JE, Draznin B. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofbrate and rosiglitazone. Diabetes Obes Metab 2007; 9: 714-23. (Pubitemid 47261853)
19. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipo pro-teinemia, oxidative stress, and the infammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007; 30: 1945-51. (Pubitemid 47219398)
20. Rosenson RS. Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus. Am J Cardiol 2007; 99: 96B-104B.
21. Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, et al. Peroxiso-me proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism. Endocrinology 2006; 147: 4252-62. (Pubitemid 44268376)
22. Voss MD, Beha A, Tennagels N, Tschank G, Herling AW, Quint M, et al. Gene expression profling in skeletal muscle of Zucker diabetic fatty rats: implications for a role of stearoyl-CoA desaturase 1 in insulin resistance Diabetologia 2005; 48: 2622-30. (Pubitemid 41738231)
23. Theilhaber J, Ulyanov A, Malanthara A, Cole J, Xu D, Nahf R, et al. GECKO: a complete large-scale gene expression analysis platform. BMC Bioinformatics 2004; 5: 195.
24. Ishida BY, Blanche PJ, Nichols AV, Yashar M, Paigen B. Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 1991; 32: 559-68.
25. Yang B, Brown KK, Chen L, Carrick KM, Clifton LG, McNulty JA, et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacol 2004; 4: 23.
26. Linz W, Wohlfart P, Baader M, Breitschofpf K, Falk E, Schäfer HL, et al. The peroxisome proliferator-activated receptor-α (PPAR-α) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin 2009; 30: 935-46.
27. Nishimura J, Dewa Y, Muguruma M, Kuroiwa Y, Yasuno H, Shima T, et al. Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. Toxicol Sci 2007; 97: 44-54. (Pubitemid 47072154)
28. Day AP, Feher MD, Chopra R, Mayne PD. The effect of bezafbrate treat ment on serum alkaline phosphatase isoenzyme activities. Meta bolism 1993; 42: 839-42. (Pubitemid 23207110)
29. Elisaf M. Effects of fbrates on serum metabolic parameters. Curr Med Res Opin 2002; 18: 269-76. (Pubitemid 35014543)